Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Syros Pharmaceuticals to Participate in Upcoming Investor Conferences

Syros Pharmaceuticals
Posted on: 08 Nov 16

Syros Pharmaceuticals (NASDAQ: SYRS) announced today that members of its management team will present a corporate overview and participate in a panel discussion at upcoming investor conferences. Details are as follows:

Stifel 2016 Healthcare Conference
Date: Tuesday, November 15
Presentation Time: 1:30 p.m. ET
Location: The Lotte New York Palace Hotel, 455 Madison Avenue, New York, NY

28 th Annual Piper Jaffray Healthcare Conference
Date: Wednesday, November 30
Panel Title: Genomic 3.0 Panel
Panel Time: 12:00-12:55 p.m. ET
Location: The Lotte New York Palace Hotel, 455 Madison Avenue, New York, NY

A live webcast of the Stifel presentation will be available on the News & Investors section of the Syros website at www.syros.com. An archived replay will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161108005090/en/

Business Wire
www.businesswire.com

Last updated on: 08/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.